Biosimilars Present New Opportunities for Insurers to Manage Cost
"Managing biosimilar drugs is a major challenge for insurers, said Marie-Hélène Dugal, Product Portfolio Manager, Drug Insurance Management Solutions for Medavie Blue Cross, during its annual seminar.
Learn more about the various approaches to consider to cover these drugs while ensuring plan sustainability. "It's all a matter of balancing access to care and the sustainability of plans."
Read the full article here (In French Only)
About Marie-Hélène
Marie-Hélène Dugal
Marie-Hélène Dugal has been with Medavie Blue Cross for 15 years. Over the course of her career, she has developed expertise in dental and health claims, benefits management and system coding by working in various departments. Four years ago, Marie-Hélène joined the Drug Management Solutions department, where she first served as a Senior Product Specialist and then as Product Portfolio Manager.
In her current role, Marie-Hélène is not only recognized as an expert in the sound management of benefits and more particularly of drug insurance programs, but she is also appreciated and highly sought after for her ability to vulgarize complex concepts in both languages. She is also invited to participate in various forums: finalist presentations, support for clients during implementation, conferences, industry committee, etc.
Marie-Hélène is one of Journal de l'assurance's Top 25 New Insurance Leaders.
CAF, RCMP, VAC